Boston Research & Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-10,978
| Closed | -$1.58M | – | 124 |
|
|
2025
Q3 | $1.58M | Sell |
10,978
-487
| -4% | -$66.5K | 0.35% | 66 |
|
|
2025
Q2 | $1.45M | Sell |
11,465
-462
| -4% | -$56.7K | 0.35% | 64 |
|
|
2025
Q1 | $1.52M | Sell |
11,927
-630
| -5% | -$85.4K | 0.38% | 62 |
|
|
2024
Q4 | $1.66M | Hold |
12,557
| – | – | 0.41% | 61 |
|
|
2024
Q3 | $1.83M | Sell |
12,557
-1,685
| -12% | -$244K | 0.43% | 61 |
|
|
2024
Q2 | $1.95M | Sell |
14,242
-545
| -4% | -$72.8K | 0.49% | 62 |
|
|
2024
Q1 | $2.03M | Sell |
14,787
-269
| -2% | -$36.7K | 0.5% | 62 |
|
|
2023
Q4 | $2.04M | Sell |
15,056
-1,210
| -7% | -$148K | 0.54% | 62 |
|
|
2023
Q3 | $1.99M | Sell |
16,266
-20
| -0.1% | -$2.54K | 0.59% | 60 |
|
|
2023
Q2 | $2.07M | Sell |
16,286
-53
| -0.3% | -$6.88K | 0.59% | 59 |
|
|
2023
Q1 | $2.11M | Sell |
16,339
-57
| -0.3% | -$7.46K | 0.63% | 57 |
|
|
2022
Q4 | $2.15M | Sell |
16,396
-305
| -2% | -$39.4K | 0.67% | 56 |
|
|
2022
Q3 | $1.95M | Buy |
16,701
+585
| +4% | +$72.6K | 0.67% | 58 |
|
|
2022
Q2 | $1.9M | Buy |
16,116
+1,500
| +10% | +$178K | 0.61% | 59 |
|
|
2022
Q1 | $1.9M | Buy |
14,616
+630
| +5% | +$82.1K | 0.55% | 61 |
|
|
2021
Q4 | $2.13M | Buy |
13,986
+300
| +2% | +$46.4K | 0.58% | 60 |
|
|
2021
Q3 | $2.21M | Buy |
13,686
+465
| +4% | +$78.3K | 0.66% | 58 |
|
|
2021
Q2 | $2.16M | Buy |
13,221
+290
| +2% | +$44.7K | 0.66% | 55 |
|
|
2021
Q1 | $1.95M | Buy |
12,931
+235
| +2% | +$37.3K | 0.63% | 56 |
|
|
2020
Q4 | $1.92M | Buy |
12,696
+105
| +0.8% | +$15K | 0.67% | 55 |
|
|
2020
Q3 | $1.7M | Sell |
12,591
-605
| -5% | -$82.1K | 0.67% | 52 |
|
|
2020
Q2 | $1.8M | Buy |
13,196
+187
| +1% | +$23.8K | 0.75% | 50 |
|
|
2020
Q1 | $1.4M | Sell |
13,009
-425
| -3% | -$48.9K | 0.7% | 49 |
|
|
2019
Q4 | $1.62M | Buy |
13,434
+150
| +1% | +$16.7K | 0.61% | 52 |
|
|
2019
Q3 | $1.32M | Buy |
13,284
+1,265
| +11% | +$132K | 0.52% | 53 |
|
|
2019
Q2 | $1.31M | Buy |
12,019
+575
| +5% | +$61.2K | 0.53% | 55 |
|
|
2019
Q1 | $1.28M | Buy |
11,444
+630
| +6% | +$69.1K | 0.53% | 54 |
|
|
2018
Q4 | $1.04M | Sell |
10,814
-1,685
| -13% | -$179K | 0.5% | 54 |
|
|
2018
Q3 | $1.52M | Buy |
12,499
+655
| +6% | +$77.1K | 0.7% | 52 |
|
|
2018
Q2 | $1.3M | Buy |
11,844
+3,330
| +39% | +$356K | 0.64% | 53 |
|
|
2018
Q1 | $908K | Buy |
8,514
+3,555
| +72% | +$394K | 0.46% | 60 |
|
|
2017
Q4 | $529K | Buy |
+4,959
| New | +$530K | 0.27% | 69 |
|
Other funds holding IBB
Boston Research & Management's IBB Position: Q4 2025 in Review
Boston Research & Management sold out of iShares Biotechnology ETF (IBB) in Q4 2025, closing a stake of 10,978 shares — an estimated $1.58M sold.
Boston Research & Management first reported a position in IBB in Q4 2017 and held it in 32 quarters. The position peaked at $2.21M in Q3 2021. 955 funds tracked by Wall St. Rank hold IBB as of Q4 2025.
- Boston Research & Management reported no remaining iShares Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
- Boston Research & Management sold 10,978 iShares Biotechnology ETF shares in Q4 2025, an estimated $1.58M.
- Boston Research & Management first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 32 quarters.
- Boston Research & Management's iShares Biotechnology ETF position peaked at $2.21M in Q3 2021.
- 955 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2025.
Based on Boston Research & Management's 13F filing for Q4 2025, filed 11 Feb 2026.